Navigation Links
Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing
Date:2/11/2011

SAN DIEGO, Feb. 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing.  This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and Roche Venture Fund.  Conatus will use the proceeds to advance the clinical development of CTS-1027, a novel clinical-stage drug candidate the Company has licensed from F. Hoffman-La Roche, Ltd. and is the subject of multiple Phase 2 clinical trials in hepatitis C (HCV)-infected patients.  

As part of the financing, Louis Lacasse from AgeChem will join the Conatus Board of Directors. "We are very excited about joining such an elite group of investors to support the development of CTS-1027 which we believe could be a blockbuster drug for the treatment of HCV infections," said Louis Lacasse.

Continuing Board Directors are Paul Klingenstein from Aberdare Ventures, Shahzad Malik, M.D., from Advent Venture Partners, William Gerber, M.D., from Bay City Capital, and Marc Perret from Gilde Healthcare, and independent directors, David Hale and Hal Van Wart, Ph.D. Steven J. Mento, Ph.D., Co-founder, President and CEO of Conatus, will continue as Chairman of the Board.

Concurrent with the first closing of the Series B financing, Conatus also converted promissory bridge notes into Series B preferred stock.

The Series B financing will remain open for an additional period as other potential investors conclude their diligence.

"This financing enables Conatus to expand the clinical development of CTS-1027 as a cell-based antiviral for the treatment of HCV infections. We believe that CTS-1027 represents a novel approach to treating HCV disease and look forward to developing this drug candidate in the HCV-null responder population in combination with the existing standard of care drugs. We also believe that CTS-1027 may be an ideal candidate for use in combination with new antiviral drugs in future all oral treatments for HCV," said Steven J. Mento Ph.D.

Conatus Pharmaceuticals Inc. is a privately-held biopharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. Conatus' lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
2. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
3. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
4. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
5. Conatus Pharmaceuticals Acquires Pfizers Idun Subsidiary
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
(Date:4/28/2016)... --  Acsis , a leading provider of supply chain ... and advisory firm IDC has named it a " ... Track and Trace Software 2016 Vendor Assessment (doc # ... the capabilities and business strategies of 10 vendors in ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... April 27, 2016 ... Forums in Zürich gab Strekin AG den ... STR001 zur Erhaltung des Resthörvermögens von Patienten, ... Für die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden ... STR001 wird während der Operation direkt ins ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 02, 2016 , ... Dr. Philip Shindler, dentist in Agoura Hills , ... the past, many necessary dental treatments could require multiple appointments to complete. This could ... extra chair time. Not only could this be inconvenient, but it could also be ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , Dr. Ramin ... Dr. Assili to receive any dental extraction treatment for $40 off the regular price. ... 2016. With the lower price, patients can more easily afford extractions to eliminate teeth ...
(Date:5/2/2016)... ... May 02, 2016 , ... This week Omega Institute, a premier nonprofit educational ... runs through October. Omega is offering a record 370 in-person workshops and new ... been such widespread interest in or need for the knowledge and skills we’ve been ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... a new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for ... results from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. ...
(Date:5/2/2016)... ... May 02, 2016 , ... Visceral fat, also known as ... kidneys, liver and pancreas. If not properly addressed, visceral fat can lead to ... Medicine, Medical Oncology and Palliative Care, warns against the dangers of visceral fat. ...
Breaking Medicine News(10 mins):